Fatma Sena Hakyemez
Research Subjects
Research Interests
Fatma Sena Hakyemez has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Abdulkerim Uygur
Cerkezkoy District Health Diroctorate, 59500 Tekirdag, Türkiye
1 shared publication Abdülkerim UygurAffiliationsİstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi
1 shared publicationFatma Sena HakyemezAffiliationsİstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi
1 shared publication- Fehmi Tabak
Department of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey
1 shared publication Fehmi TabakAffiliationsİstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi
1 shared publicationHalk Sağlığı Anabilim Dalı
1 shared publication
Latest Publications
- Open Access
- 30 September 2023
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 36 (3) , 208-215
Morbidity and Mortality in Immunocompromised COVID-19 Patients: Which Factors Are Responsible?
Objective: The COVID-19 pandemic has caused significant morbidity and mortality and has challenged health systems worldwide. Immunosuppression is considered a risk factor for development of severe COVID-19. In this study, we aimed to determine the factors affecting morbidity and mortality in immunocompromised patients diagnosed with COVID-19. Methods: In this retrospective, cross-sectional study, laboratory findings and outcomes of 340 COVID-19 patients with secondary immunosuppression in a university hospital in Turkey from March 2020 to April 2022 were analyzed according to the 28-day clinical outcomes. Mortality-related factors were investigated in 3 patient groups with different forms of immunodeficiency: 1) malignancy (hematologic/solid), 2) organ transplantation, and 3) rheumatological diseases. Results: 172 (51%) of the patients were female, and the mean age was 61±15 years. A total of 122 (35.8%) patients died during hospitalization. The mortality rate (73.4%) in patients admitted to the intensive care unit (ICU) was significantly higher than those not admitted (pppp=0.029) and nasal oxygen support (p<0.001) led to a decrease in the risk of mortality. Conclusion: Immunocompromised patients are at risk for serious COVID-19 complications. LDH, D-dimer, CRP, and lymphocyte values can be used as markers to evaluate survival, and standard treatment is essential in immunosuppressive COVID-19 patients.
- 30 September 2023
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 36 (3) , 208-215
Open AccessMorbidity and Mortality in Immunocompromised COVID-19 Patients: Which Factors Are Responsible?
Objective: The COVID-19 pandemic has caused significant morbidity and mortality and has challenged health systems worldwide. Immunosuppression is considered a risk factor for development of severe COVID-19. In this study, we aimed to determine the factors affecting morbidity and mortality in immunocompromised patients diagnosed with COVID-19. Methods: In this retrospective, cross-sectional study, laboratory findings and outcomes of 340 COVID-19 patients with secondary immunosuppression in a university hospital in Turkey from March 2020 to April 2022 were analyzed according to the 28-day clinical outcomes. Mortality-related factors were investigated in 3 patient groups with different forms of immunodeficiency: 1) malignancy (hematologic/solid), 2) organ transplantation, and 3) rheumatological diseases. Results: 172 (51%) of the patients were female, and the mean age was 61±15 years. A total of 122 (35.8%) patients died during hospitalization. The mortality rate (73.4%) in patients admitted to the intensive care unit (ICU) was significantly higher than those not admitted (pppp=0.029) and nasal oxygen support (p<0.001) led to a decrease in the risk of mortality. Conclusion: Immunocompromised patients are at risk for serious COVID-19 complications. LDH, D-dimer, CRP, and lymphocyte values can be used as markers to evaluate survival, and standard treatment is essential in immunosuppressive COVID-19 patients.